Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Telix Pharmaceuticals (Innovations) Pty Limited
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
The New York Proton Center
Novelwise Pharmaceutical Corporation
Iambic Therapeutics, Inc
Parabilis Medicines, Inc.
NaviFUS Corporation
NaviFUS Corporation
Stemline Therapeutics, Inc.
Ottawa Hospital Research Institute
Avera McKennan Hospital & University Health Center
Pfizer
National Institutes of Health Clinical Center (CC)
Rigel Pharmaceuticals
RasCal Therapeutics, Inc.
Beijing Tiantan Hospital
UMC Utrecht
The Children's Hospital of Zhejiang University School of Medicine
Baptist Health South Florida
GT Medical Technologies, Inc.
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Essen Biotech
Essen Biotech
Medical University of South Carolina
Uppsala University
Australian & New Zealand Children's Haematology/Oncology Group
Mayo Clinic
University of Maryland, Baltimore
Telix Pharmaceuticals (Innovations) Pty Limited
Dysplasia Diagnostics Limited
Var2 Pharmaceuticals
Institut du Cancer de Montpellier - Val d'Aurelle
Odense University Hospital
Degron Therapeutics Co.
University Health Network, Toronto
Cancer Research UK
Cancer Research UK
Cancer Research UK
Cancer Research UK
Nested Therapeutics, Inc
St. Jude Children's Research Hospital
Massive Bio, Inc.
M.D. Anderson Cancer Center
Xiangya Hospital of Central South University
RefleXion Medical